Mansfield, MA (November 6, 2014): NECI announced a new partnership agreement with CONTINUUS Pharmaceuticals, a revolutionary spin-out company from the Massachusetts Institute of Technology (MIT). This agreement will create a path for CONTINUUS to bring their Integrated Continuous Manufacturing (ICM) process to the life sciences marketplace using Emerson’s DeltaV™ distributed control system and Syncade™ manufacturing execution system (MES).
The DeltaV system controls each step of the ICM process, while Syncade provides work process instructions to the operator so that necessary actions are completed correctly and at the right time. By implementing the innovative CONTINUUS technology, pharmaceutical manufacturers can eliminate step-by-step requirements of a traditional batch process. Instead, they can apply an integrated, continuous manufacturing methodology that simplifies the path from raw materials used in the synthesis of the active ingredient to the final dosage form. Pharmaceutical manufacturers can produce medicines at significantly reduced costs (50% reduction), with reduced lead times (90% reduction from industry standard), all while improving quality.
“CONTINUUS Pharmaceuticals’ breakthrough ICM technology for the life science industry is positioned to be a catalyst for change in an industry which operates exclusively in a batch environment,” said Mark Genest, senior account manager with NECI. “This technology will have a positive impact in both time to market and cost of manufacturing for those companies using it.”
“We have undertaken the most revolutionary approach to continuous manufacturing, where a set of new process technologies runs simultaneously, under fully automated control, from the beginning to the end of the process. This requires complex automation and an integrated control strategy of our plants. The partnership with NECI will provide us with advanced and flexible control architecture for our processes, and we are very excited about our collaboration,” said Salvatore Mascia, Founder and CEO of CONTINUUS Pharmaceuticals.
“NECI is excited to partner with CONTINUUS Pharmaceuticals. The DeltaV system and Syncade MES will be engineered to enable the rapid deployment of the ICM process providing significant ‘on-demand’ manufacturing advantages to their customers,” said Tom Ramundo, President of NECI.
CONTINUUS will initially utilize the Guest Center at NECI’ headquarters in Mansfield, Massachusetts to provide a location for customer demonstrations of the ICM process via a DeltaV simulation system. In the future, a full-scale DeltaV development system is planned to be installed in CONTINUUS’ pilot plant in Woburn, Massachusetts.
NECI delivers a broad scope of products along with the engineering, training, maintenance and asset reliability services required to solve process control needs. As a Local Business Partner of Emerson, NECI serves the life sciences, power generation, pulp & paper, gas distribution & transmission, water & wastewater and various other industries.
Learn more at: www.NECI.com
Emerson (www.Emerson.com) is a leader in helping businesses automate their production, processing and distribution in the chemical, oil and gas, refining, pulp and paper, power, water and wastewater treatment, mining and metals, food and beverage, life sciences and other industries. The company combines superior products and technology with industry-specific engineering, consulting, project management and maintenance services. Its brands include PlantWeb™, Syncade™, DeltaV™, Fisher®, Bettis™, Micro Motion®, Rosemount®, Daniel™, Ovation™ and AMS Suite.
About CONTINUUS Pharmaceuticals
CONTINUUS Pharmaceuticals is a spin-out company of the $65 million collaboration between MIT and Novartis on continuous manufacturing. CONTINUUS designs and develops integrated continuous manufacturing processes for pharmaceutical clients, providing them with an exceptional, “one-shop solution” for the entire development and manufacturing cycle.
Learn more at: http://continuuspharma.com